

## PROVINCIAL FUNDING SUMMARY

Crizotinib (Xalkori) for Non-Small Cell Lung Cancer, first-line (pCODR10054)

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: August 6, 2015

This information is current as of October 5, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Dec 1, 2015	Advanced non-small cell lung cancer: <ul style="list-style-type: none"> <li>Laboratory confirmed anaplastic lymphoma kinase (ALK)-positive tumour</li> <li>ECOG 0-2</li> <li>First-line monotherapy</li> </ul> A BC Cancer Agency Compassionate Access Program (CAP) approval must be obtained
AB	Funded	Dec 18, 2015	Crizotinib as monotherapy for use in patients with anaplastic lymphoma kinase (ALK) positive advance (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).
SK	Funded	Dec 28, 2015	First line treatment of patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) with an ECOG performance status of 0, 1 or 2, until disease progression or unacceptable toxicity.
MB	Funded	Jan 18, 2016	For the first line-therapy for patients with an ALK-positive non-small cell lung cancer (NSCLC) with an ECOG performance status of 0-2.
ON	Funded	Dec 4, 2015	For first-line therapy for patients with ALK-positive advanced non-small cell lung cancer (NSCLC) with ECOG performance status $\leq 2$ . Exclusion Criteria: Patients who have progressed during or following first-line therapy with crizotinib are not eligible to receive crizotinib as a second-line therapy.
NS	Funded	May 2, 2016	As a first-line therapy for patients with ALK-positive advanced non-small cell lung cancer with ECOG performance status $\leq 2$ .

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
NB	Funded	Apr 12, 2016	First-line therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) with an ECOG performance status of 0-2. Requests for continued coverage will be considered if tumour regression continues or the disease is stable and cancer related symptoms have improved. Coverage will not be considered for “psychological” palliation of progressive disease.
NL	Funded	Feb 1, 2016	First-line therapy for patients with an ALK-positive NSCLC with an ECOG performance status of 0-2. Renewals will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of crizotinib.
PEI	Funded	Aug 1, 2018	For use as a first or second-line therapy for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC) with ECOG performance status $\leq 2$ . The request for coverage must be made and the medication prescribed by a specialist in haematology or medical oncology, or a general practitioner acting under the direction of those specialists.